Burjassot

• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma
• A clinical trial to assess the efficacy and safety of ADX-308, a new type of treatment for Geographic Atrophy (GA), an advanced stage of eye … Pending
  2025-521779-30-00 4 Geographic atrophy secondary to age-related macular degeneration
• A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio … Pending
  2025-523704-77-00 4 Geographic atrophy secondary to age-related macular degeneration
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting
  2025-522701-38-00 6 2026-02-26 SUBRETINAL HYPERREFLECTIVE MATERIAL
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting
  2024-517545-13-00 11 2025-06-04 Neovascular Age-Related Macular Degeneration
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended recruitment
  2024-516745-39-00 4 2025-07-11 Cutaneous lupus erythematosus
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema … Ended recruitment
  2024-510944-30-00 10 2024-11-22 Diabetic Macular Edema
• ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub … Ended recruitment
  2024-511482-11-00 5 2024-11-20 Dry Age-Related Macular Degeneration (Dry AMD)
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine … Ended recruitment
  2024-516315-24-00 5 2022-05-27 myopia
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 5 2021-09-23 Neovascular age-related macular degeneration (wet AMD)
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)

Showing 1–24 of 24 trials